182 related articles for article (PubMed ID: 35000092)
1. Factors leading to alpelisib discontinuation in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative breast cancer.
Cheung YM; Cromwell GE; Tolaney SM; Min L; McDonnell ME
Breast Cancer Res Treat; 2022 Apr; 192(2):303-311. PubMed ID: 35000092
[TBL] [Abstract][Full Text] [Related]
2. Alpelisib for
André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
[TBL] [Abstract][Full Text] [Related]
4. A Phase II Randomized Study of Neoadjuvant Letrozole Plus Alpelisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB).
Mayer IA; Prat A; Egle D; Blau S; Fidalgo JAP; Gnant M; Fasching PA; Colleoni M; Wolff AC; Winer EP; Singer CF; Hurvitz S; Estévez LG; van Dam PA; Kümmel S; Mundhenke C; Holmes F; Babbar N; Charbonnier L; Diaz-Padilla I; Vogl FD; Sellami D; Arteaga CL
Clin Cancer Res; 2019 May; 25(10):2975-2987. PubMed ID: 30723140
[TBL] [Abstract][Full Text] [Related]
5. A Cohort Study of the Antitumor Efficacy and Toxicity Profile of Alpelisib for Metastatic or Locally Advanced HR+, HER2- Breast Cancer: A Single-Institution Experience.
Sarfraz H; Bari S; Whiting J; Sur M; Mo Q; Armitage M; Costa RLB
Oncology; 2024; 102(5):414-424. PubMed ID: 38011835
[TBL] [Abstract][Full Text] [Related]
6. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
[TBL] [Abstract][Full Text] [Related]
7. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS
Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021
[TBL] [Abstract][Full Text] [Related]
8. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
[TBL] [Abstract][Full Text] [Related]
9. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Rugo HS; André F; Yamashita T; Cerda H; Toledano I; Stemmer SM; Jurado JC; Juric D; Mayer I; Ciruelos EM; Iwata H; Conte P; Campone M; Wilke C; Mills D; Lteif A; Miller M; Gaudenzi F; Loibl S
Ann Oncol; 2020 Aug; 31(8):1001-1010. PubMed ID: 32416251
[TBL] [Abstract][Full Text] [Related]
10. Patient-Reported Outcomes in Patients With
Ciruelos EM; Rugo HS; Mayer IA; Levy C; Forget F; Delgado Mingorance JI; Safra T; Masuda N; Park YH; Juric D; Conte P; Campone M; Loibl S; Iwata H; Zhou X; Park J; Ridolfi A; Lorenzo I; André F
J Clin Oncol; 2021 Jun; 39(18):2005-2015. PubMed ID: 33780274
[TBL] [Abstract][Full Text] [Related]
11. Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications.
Vernieri C; Corti F; Nichetti F; Ligorio F; Manglaviti S; Zattarin E; Rea CG; Capri G; Bianchi GV; de Braud F
Breast Cancer Res; 2020 Apr; 22(1):33. PubMed ID: 32252811
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of alpelisib (BYL-719) and trastuzumab emtansine (T-DM1) in HER2-positive metastatic breast cancer (MBC) after trastuzumab and taxane therapy.
Jain S; Shah AN; Santa-Maria CA; Siziopikou K; Rademaker A; Helenowski I; Cristofanilli M; Gradishar WJ
Breast Cancer Res Treat; 2018 Sep; 171(2):371-381. PubMed ID: 29850984
[TBL] [Abstract][Full Text] [Related]
13. Incidence, risk factors, and management of alpelisib-associated hyperglycemia in metastatic breast cancer.
Shen S; Chen Y; Carpio A; Chang C; Iyengar NM
Cancer; 2023 Dec; 129(24):3854-3861. PubMed ID: 37743730
[TBL] [Abstract][Full Text] [Related]
14. A pharmacokinetic evaluation of alpelisib for the treatment of HR+, HER2-negative, PIK3CA-mutated advanced or metastatic breast cancer.
Bertho M; Patsouris A; Augereau P; Robert M; Frenel JS; Blonz C; Campone M
Expert Opin Drug Metab Toxicol; 2021 Feb; 17(2):139-152. PubMed ID: 33213227
[No Abstract] [Full Text] [Related]
15. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
[TBL] [Abstract][Full Text] [Related]
16. Alpelisib for the treatment of
Leenhardt F; Alexandre M; Jacot W
Expert Opin Pharmacother; 2021 Apr; 22(6):667-675. PubMed ID: 33622114
[No Abstract] [Full Text] [Related]
17. Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer.
Burnette SE; Poehlein E; Lee HJ; Force J; Westbrook K; Moore HN
Breast Cancer Res Treat; 2023 Jan; 197(2):369-376. PubMed ID: 36409396
[TBL] [Abstract][Full Text] [Related]
18. A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer.
Lu YS; Lee KS; Chao TY; Tseng LM; Chitapanarux I; Chen SC; Liu CT; Sohn J; Kim JH; Chang YC; Yang Y; Shotelersuk K; Jung KH; Valenti R; Slader C; Gao M; Park YH
Clin Cancer Res; 2021 Jan; 27(2):408-417. PubMed ID: 32718997
[TBL] [Abstract][Full Text] [Related]
19. Predicting Hyperglycemia Among Patients Receiving Alpelisib Plus Fulvestrant for Metastatic Breast Cancer.
Ge X; Behrendt CE; Yost SE; Patel N; Samoa R; Stewart D; Sedrak M; Lavasani S; Waisman J; Yuan Y; Mortimer J
Oncologist; 2023 Jul; 28(7):e488-e492. PubMed ID: 36943382
[TBL] [Abstract][Full Text] [Related]
20. Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program.
Bello Roufai D; Gonçalves A; De La Motte Rouge T; Akla S; Blonz C; Grenier J; Gligorov J; Saghatchian M; Bailleux C; Simon H; Desmoulins I; Tharin Z; Renaud E; Bertho M; Benderra MA; Delaloge S; Robert L; Cottu P; Pierga JY; Loirat D; Bertucci A; Renouf B; Bidard FC; Lerebours F
Oncogene; 2023 Jun; 42(23):1951-1956. PubMed ID: 36611120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]